This Is MS Multiple Sclerosis Community: Knowledge & Support

Glatiramer acetate (GA) reduces fatigue in multiple sclerosis patients more than interferon beta-1b (IFN-1b) after 1 year of treatment, according to a new study.

IFN-1b had no impact on two clinical measures of fatigue, while GA (Copaxone) reduced the score on the Fatigue Severity Scale (FSS) by 20%, and the score on the Fatigue Descriptive Scale (FDS) by 34%, according to a study presented here at the European Committee for Treatment and Research in Multiple Sclerosis meeting.

Based on the results, the authors, Tatiana Shmidt and a colleague at the Kozhevnikov Clinic for Neurological Diseases in Moscow, Russia, concluded in their poster, "Copaxone is recommended as a first-line imunomodulating drug for patients with severe fatigue." The authors were unavailable for comment at press time.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1767

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis